We are live on ! Find out more
MREO

Mereo BioPharma
MREO

64 hedge funds and large institutions have $182M invested in Mereo BioPharma in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,970% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $107K

101% more capital invested

Capital invested by funds: $90.4M → $182M (+$91.2M)

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

46% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 13

14% more funds holding

Funds holding: 56 → 64 (+8)

1.15% more ownership

Funds ownership: 10.06% → 11.21% (+1.2%)

Holders
64
Holders Change
+8
Holders Change %
+14.29%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
17
Increased
19
Reduced
13
Closed
9
Calls
$2.21M
Puts
$107K
Net Calls
+$2.11M
Net Calls Change
+$1.45M

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$6.16M
2
RCMNY
Rubric Capital Management (New York)
New York
+$3.7M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.54M
4
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.97M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$956K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$3.67M
2
JGC
J. Goldman & Co
New York
-$542K
3
FAM
Formidable Asset Management
Ohio
-$428K
4
DCM
DAFNA Capital Management
California
-$351K
5
JP Morgan Chase
JP Morgan Chase
New York
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$31.3M +$3.7M +1,936,877 +17%
SCM
2
Soleus Capital Management
Connecticut
$22.6M +$191K +100,000 +1%
MP
3
Mangrove Partners
Connecticut
$20.2M +$6.16M +3,221,346 +58%
RSCM
4
Rock Springs Capital Management
Maryland
$18.4M +$588K +307,370 +4%
SCM
5
Suvretta Capital Management
New York
$17M +$12.2K +6,400 +0.1%
6CM
6
683 Capital Management
New York
$14.3M +$383K +200,000 +3%
Alkeon Capital Management
7
Alkeon Capital Management
New York
$9.79M +$956K +500,000 +13%
TC
8
Tejara Capital
United Kingdom
$8.58M +$953K +498,128 +15%
CC
9
Clearline Capital
New York
$7.68M +$428K +223,995 +7%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$6.12M +$3.54M +1,850,000 +231%
Goldman Sachs
11
Goldman Sachs
New York
$4.67M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$4.15M +$135K +70,439 +4%
Aberdeen Group
13
Aberdeen Group
United Kingdom
$3.58M +$2.97M +1,551,082 New
Millennium Management
14
Millennium Management
New York
$3.26M +$319K +166,732 +13%
DCM
15
DAFNA Capital Management
California
$1.8M -$351K -183,700 -19%
MAM
16
Monaco Asset Management
Monaco
$1.56M +$154K +80,765 +14%
NIM
17
NEOS Investment Management
Connecticut
$813K +$594K +310,577 +751%
Citadel Advisors
18
Citadel Advisors
Florida
$750K -$3.67M -1,917,606 -86%
TI
19
Tidal Investments
Wisconsin
$738K -$24K -12,524 -4%
Two Sigma Investments
20
Two Sigma Investments
New York
$719K +$322K +168,458 +118%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$406K +$138K +72,358 +70%
JGC
22
J. Goldman & Co
New York
$374K -$542K -283,485 -64%
KCM
23
Knoll Capital Management
Florida
$370K +$307K +160,470 New
Morgan Stanley
24
Morgan Stanley
New York
$352K +$279K +145,637 +2,176%
FAM
25
Fred Alger Management
New York
$237K +$196K +102,531 New
1
2 3

MREO Hedge Fund Activity: Q4 2023 in Review

64 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2023, worth a combined $182M — up 101% from $90.4M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MREO positions and 9 closed out — a net gain of 8 holders — while 19 added to existing stakes and 13 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $6.16M. The largest seller was Citadel Advisors, cutting an estimated $3.67M.

  • 64 institutional investors held Mereo BioPharma (MREO) as of Q4 2023, up from 56 in Q3 2023.
  • Funds reported $182M of Mereo BioPharma stock for Q4 2023, up 101% quarter-over-quarter.
  • 17 funds opened new Mereo BioPharma positions in Q4 2023 and 9 closed out, a net change of +8 holders.
  • The largest Mereo BioPharma buyer in Q4 2023 was Mangrove Partners, an estimated $6.16M added.
  • The largest Mereo BioPharma seller in Q4 2023 was Citadel Advisors, an estimated $3.67M sold.

Based on aggregated 13F filings for Q4 2023.